Effect of Physical Exercise in Alzheimer Patients

Overview

Background: Current treatment for Alzheimer's disease (AD) is symptomatic and can only temporarily slow down progression. Exercise has the potential to improve cognition, psychological symptoms, physical performance and quality of life, but evidence is scarce. Previous trials are short, often underpowered and involving home based light exercise programs. Most have included nursing homes residents with severe or undefined dementia. The aim of the ADEX trial is to establish whether exercise is effective in improving cognition, physical performance and quality of life as well as reducing the prevalence of psychological symptoms among AD patients. Methods: The ADEX Trial is a multicentre, single-blind, randomized clinical trial. Based on power calculations the investigators plan to recruit 192 home-dwelling patients aged 50-90 years with mild to moderate AD. The participants will be randomly allocated into two groups: An intervention group attending 16 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week and a control group only receiving usual care. The hypothesis is that aerobic exercise will improve physical function, the cognitive and daily functioning and quality of life in people with mild to moderate AS. Blood sampling will be performed in all subjects to examine effects on biomarkers. A subgroup of the patients will also undergo MRI, PiB-PET and lumbar puncture to investigate structural changes and β-amyloid accumulation. Further, a health-economic analysis will be performed. Recruitment was started in January 2012. Last study visits are planned to be performed in January 2014 and results will be available in 2014. This RCT will contribute to evidence regarding the potential effects of a systematic program of physical exercise for patients with Alzheimer's disease.

Full Title of Study: “Preserving Quality of Life, Physical Health and Functional Ability in Alzheimer’s Disease: The Effect of Physical Exercise”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: January 2014

Detailed Description

see protocol article

Interventions

  • Other: Aerobic exercise
    • Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.

Arms, Groups and Cohorts

  • Active Comparator: Intervention group
    • 16 weeks of aerobic exercise
  • No Intervention: Control group
    • Usual care.

Clinical Trial Outcome Measures

Primary Measures

  • Symbol Digit Modalities Test
    • Time Frame: Change in score from baseline to 16 weeks

Secondary Measures

  • NPI (psychological symptoms.)
    • Time Frame: Change in score from baseline to 16 weeks
  • Astrand submaximal bicycle test for estimating VO2 max
    • Time Frame: Change in score from baseline to 16 weeks
  • Euro-qol-5D-5L (health related quality of life)
    • Time Frame: Change in score from baseline to 16 weeks
  • Alzheimer’s disease Assessment Scale – Cognitive section (ADAS-cog).
    • Time Frame: Change in score from baseline to 16 weeks
  • Changes in physical fitness
    • Time Frame: Change in score from baseline to 16 weeks
    • Timed up and go test (TUG), 10 m walk, 10m Dual-Task, 400m fast walking, Sit-to-stand (number in 30 sec.)(STS).
  • Self-efficacy scale
    • Time Frame: Change in score from baseline to 16 weeks
  • Verbal fluency
    • Time Frame: Change in score from baseline to 16 weeks
  • Stroop
    • Time Frame: Change in score from baseline to 16 weeks
  • MMSE (Mini Mental State Examination)
    • Time Frame: Change in score from baseline to 16 weeks

Participating in This Clinical Trial

Inclusion Criteria

Inclusion criteria are (table 1)

  • Age between 50 and 90 years – A score of 20 or more on the Mini Mental State Examination (MMSE) – Imaging (CT or MR of cerebrum) consistent with AD – Have a caregiver with regular contact to the participant (more than once a month) who is also willing to participate in the study – In general good health allowing the participant to participate in physical exercise. – At least 7 years of schooling and Danish speaking – Visual acuity and hearing must permit neuropsychological testing. – If the patient is receiving anti-dementia medication or mood stabilizing medication, these must have been given in stable doses for at least 3 months. Exclusion Criteria:

  • Participation in aerobic exercise (moderate to hard intensity) more than 2 times a week on a regular basis. – Any musculoskeletal or joint impairment that could interfere with completion of the study (significant joint problems, back pain or pain in arms and legs that provide problems with mobility in daily activities) – Male participants with a combination of two or more of the following risk factors even if asymptomatic: smokers, hypertension and hypercholesterolemia – Major neurologic (other than AD), cardiac or other medical diseases that constitutes a contraindication to physical activity. Stent operation or previous myocardial infarction is not an exclusion criteria if the participant has had a recent (within 3 months) normal exercise tests . – Severe cerebro vascular disease judged from the CT or MR scans and remarkable hypertension defined as Systolic blood pressure >180 and diastolic >100 – Severe psychiatric disease, as well as alcohol or drug abuse within the last 2 years

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rigshospitalet, Denmark
  • Provider of Information About this Clinical Study
    • Principal Investigator: Steen G Hasselbalch, Associate Professor – Rigshospitalet, Denmark
  • Overall Official(s)
    • Steen G Hasselbalch, Professor, Principal Investigator, Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital, Rigshospitalet

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.